- Global Pharma News & Resources

Drug discovery company Engitix Therapeutics to relocate headquarters to White City Place

Stanhope, Mitsui Fudosan and AIMCo are delighted to announce today that Engitix Therapeutics is the latest life science company to sign an agreement to move its headquarters to White City Place, the 1.9 m sq ft business, innovation and creative district in West London.

Engitix is taking 8,000 square feet of space in the WestWorks building for its new UK headquarters and laboratory and will be moving on to the site later this year.

Engitix is a biotech company developing a portfolio of drug discovery programmes in fibrosis and solid tumours using its proprietary human extracellular matrix (ECM)-based discovery platform. The use of physiologically realistic human in vitro models is transforming the ability to identify new drug targets, determine biological mechanisms of action and increase the success rate of therapeutic candidates gaining regulatory approval.

Engitix is the latest in a host of life science companies which have moved their headquarters to White City Place, as the campus has quickly established itself as one of the UK’s most desirable locations for innovative businesses in the sector. They will be joining fellow life sciences biotech companies Gama Delta, Autolus and Synthace who have their head offices at White City Place, as well as global pharmaceutical company Novartis who also relocated their UK headquarters to the campus.

David Camp, CEO, Stanhope stated:

“We are delighted that Engitix have decided to relocate their Head Office to the growing life sciences cluster at the WestWorks building in White City Place. The addition of Engitix Therapeutics helps further enhance White City Place’s status as the number one location of choice for innovative, forward thinking companies in the life sciences and biotech sector.”

Tomoo Nakamura, Managing Director, Mitsui Fudosan UK said:

“The decision by Engitix to move their UK headquarters and laboratory to White City Place, means that they will join a host of world leading companies, like Novartis, located at our White City business campus. The move helps cement White City Place as a key destination for ambitious innovative businesses seeking world class modern facilities, a prime location and very good transport links.”

Stephen Brindle, COO, Engitix said:

“The move to WestWorks is a hugely important milestone for our business as we take the next steps in developing our innovative drug development platform.  Being located at White City Place gives us access to world class facilities, access to an established life sciences network, and will help us attract the best talent to Engitix also”

Other tenants in the WestWorks include ITV Studios who have 350 staff located on-site, haute couture fashion brand Ralph and Russo and global fashion supply chain management specialist Li & Fung. Work on a new 120,000 square foot building on the Gateway Site is due to begin this year, with French beauty and cosmetics firm L’Oreal having already announced plans to relocate their UK head office to six floors of the new building.

As well as housing ‘The Studio’, a state of the art 100-seater space equipped with the latest technology in audio and visual recording, White City Place also boasts a range of amenities including fitness studios, restaurants, bars and cafes. 

Engitix was advised by Hanover Green LLP. Stanhope was advised by Cushman and Wakefield and Macfarlanes

Drug discovery company Engitix Therapeutics to relocate headquarters to White City Place

Editor Details

Related Links

Last Updated: 02-Sep-2020